Renin‐angiotensin blockade ameliorates the progression of glomerular injury in podocyte‐specific Ctcf knockout mice
Nephrology · 2024
DOI: 10.1111/nep.14400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology, 2024. Verfasst von Keisuke Fujioka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan. Hauptthemen laut MEDLINE: Podocytes, Mice, Knockout, Proteinuria, CCCTC-Binding Factor. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aim
Several studies have shown that the progression of proteinuria and renal tissue injury is associated with activation of the intrarenal renin‐angiotensin system (RAS). CCCTC‐binding factor (CTCF) is a DNA‐binding factor that plays an essential role in the regulation of gene expression. In the present study, we aimed to investigate the phenotypic effects of CTCF deficiency in podocytes.
Methods
Angiotensin II type 1 receptor blockers (ARBs) were administered to the podocyte‐specific Ctcf knockout mice, and histological and biochemical analyzes were performed. We also investigated the changes in the expression of podocin in podocyte cell cultures with or without stimulation with angiotensin II from glomeruli isolated using magnetic beads from podocyte‐specific Ctcf knockout mice.
Results
Mice in which Ctcf was deleted from podocytes developed glomerulopathy and mice developed severe progressive proteinuria, and impaired renal function. Moreover, ARBs suppressed the development of glomerulopathy in podocyte‐specific Ctcf knockout mice. Both real‐time polymerase chain reaction and western blotting showed that podocin expression was decreased in cell cultures stimulated with angiotensin II. Furthermore, RAS components gene expressions in podocyte cell cultures isolated from podocyte‐specific Ctcf knockout mice were significantly increased.
Conclusion
These results suggest that RAS is involved in the development of glomerulopathy in podocyte‐specific Ctcf knockout mice. Elucidation of the pathophysiology of podocyte‐specific Ctcf knockout mice may provide new insights into the relationship between podocyte injury and chronic glomerulonephritis. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan.
- Department of Immunology and Parasitology, Graduate School of Medicine, Tokushima University, Tokushima, Japan.
- Department of Cell Biology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Anatomy and Developmental Neurobiology, Tokushima University Graduate School of Medical Sciences, Tokushima, Japan.
- Department of Cell Biology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
ORCID-Profile: Maki Urushihara
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Fujioka, K., Nagai, T., Hattori, T., Kagami, S., Yasutomo, K., Galjart, N., Hirayama, T., Kawachi, H., & Urushihara, M. (2024). Renin‐angiotensin blockade ameliorates the progression of glomerular injury in podocyte‐specific Ctcf knockout mice. Nephrology. https://doi.org/10.1111/nep.14400
Vancouver
Fujioka K, Nagai T, Hattori T, Kagami S, Yasutomo K, Galjart N, et al. Renin‐angiotensin blockade ameliorates the progression of glomerular injury in podocyte‐specific Ctcf knockout mice. Nephrology. 2024. doi:10.1111/nep.14400
BibTeX
@article{Fujioka2024,
author = {Fujioka, Keisuke and Nagai, Takashi and Hattori, Tomoki and Kagami, Shoji and Yasutomo, Koji and Galjart, Niels and Hirayama, Teruyoshi and Kawachi, Hiroshi and Urushihara, Maki},
title = {Renin‐angiotensin blockade ameliorates the progression of glomerular injury in podocyte‐specific Ctcf knockout mice},
journal = {Nephrology},
year = {2024},
doi = {10.1111/nep.14400}
}
EUVIMED